变应性鼻炎患者下鼻甲黏膜注射地塞米松的疗效观测

目的观测下鼻甲注射地塞米松对变应性鼻炎患者的临床疗效及对患者血清IFN-γ、IL-4含量的疗效。方法随机抽取2008年9月至2011年9月来我院门诊治疗及住院治疗的患者96例为治疗组，另选同期入院体检的96例健康体检者作为对照组，观测于下鼻甲注射地塞米松对变应性鼻炎患者的临床疗效及两组血清IFN-γ、IL-4含量的变化。结果治疗后，治疗组显效59例（61．45％），有效32例（33．33％），无效5例（5．21％），总有效率94．79％。患者出现的喷涕、鼻塞、鼻痒、流清水样鼻涕、伴或不伴嗅觉减退等临床症状及体征，其评分均较治疗前明显降低（P〈0．05）。治疗前治疗组的IL4含量明显高于对照组，IFN-γ的含量明显低于对照组（P〈0．01），治疗后治疗组IL-4、IFN-γ含量分别与治疗前比较，差异有统计学意义（P〈0．01）。结论注射地塞米松于下鼻甲治疗变应性鼻炎有效率高，能明显改善患者的临床症状及体征，并通过调节IFN-γ、IL-6含量的变化有效阻止变态反应性炎症的发生。

Curative effect of inject in dexamethasone at inferior turbinate in patients with allergicrhinitis

Objective To observe the inferior turbinate injection of dexamethasone on clinical efficacy in patients with allergic rhinitisand allergic rhinitis patients on IFN-γ, IL-4 content. Methods The observation group were 96 patients in our hospital from September 2008 to 2010 September outpatients and inpatients in patients admitted to hospital over the same period replacement of the physical examination of the 60 healthy subjects as control group, dexamethasone observed on the inferior turbinate clinical efficacy in patients with allergic rhinitis, and two serum IFN-γ, IL-4 content changes. Results Group by two courses of treatment, effective in 59 cases（61.46% ）were cured,32 cases（33.33% ） ,5 cases（5.21% ） ,the total effective rate was 94.79%. Observation group,96 patients appeared sneezing, nasal itching, nasal congestion, nasal discharge flow like water, with or without olfactory loss and other clinical symptoms and signs after treatment, the score was significantly lower than before treatment（ P 〈 0.05 ）. Before treatment, IL-4 observation group was significantly higher than in healthy controls, IFN-γ were significantly lower than the control group （ P 〈 0. 01 ）. There was significant difference after treatment in IL-4, IFH-γ levels between the observation group and the control group（ P 〈 0. 01 ）. Conclusion The injection of dexamethasone in the treatment of inferior turbinate effective rate of allergic rhinitis can significantly improve clinical symptoms and signs, dexamethasone, by regulating IFN-γ, IL-6 content changes, which further prevents allergic inflammation place.